Log In
BCIQ
Print this Print this
 

eluxadoline (Viberzi) (JNJ-270189066)

Also known as: MuDelta

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionLocally acting mu opioid receptor (MOR; OPRM1) agonist and delta opioid receptor antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1) ; Opioid receptor delta 1 (OPRD1) (DOR)
Mechanism of ActionMu opioid receptor agonist; Delta opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIrritable bowel syndrome
Indication DetailsTreat diarrhea-predominant irritable bowel syndrome (IBS-D)
Regulatory Designation U.S. - Fast Track (Treat diarrhea-predominant irritable bowel syndrome (IBS-D));
U.S. - Priority Review (Treat diarrhea-predominant irritable bowel syndrome (IBS-D))
PartnerAllergan plc;
Ironwood Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,460.0M

$1,100.0M

$360.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2015

Undisclosed

0

Undisclosed

07/02/2014

$1,460.0M

$1,100.0M

$360.0M

Get a free BioCentury trial today